KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2025)

Acadia Pharmaceuticals (ACAD) has 8 years of Work In Process data on record, last reported at $2.6 million in Q4 2025.

  • For Q4 2025, Work In Process fell 96.22% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, down 96.22%, while the annual FY2025 figure was $2.6 million, 96.22% down from the prior year.
  • Work In Process reached $2.6 million in Q4 2025 per ACAD's latest filing, down from $3.2 million in the prior quarter.
  • Across five years, Work In Process topped out at $69.7 million in Q4 2024 and bottomed at $2.6 million in Q1 2025.
  • Average Work In Process over 5 years is $9.3 million, with a median of $5.1 million recorded in 2022.
  • Peak YoY movement for Work In Process: skyrocketed 1587.01% in 2024, then plummeted 96.22% in 2025.
  • A 5-year view of Work In Process shows it stood at $6.2 million in 2021, then decreased by 20.8% to $4.9 million in 2022, then fell by 16.04% to $4.1 million in 2023, then surged by 1587.01% to $69.7 million in 2024, then tumbled by 96.22% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $2.6 million in Q4 2025, $3.2 million in Q3 2025, and $3.4 million in Q2 2025.